Oslo, Norway, April 10, 2025 - Lytix Biopharma AS ("Lytix") (Euronext Growth
Oslo: LYTIX), a clinical stage immuno-oncology company, has today published its
Annual Report for 2024, which was approved by the board of directors on April 9,
2024.

2024 marked a defining year for Lytix, with significant clinical progress and
strategic milestones that further de-risk and validate the company's unique
immuno-oncology platform. 

"2024 has been a transformative year for Lytix Biopharma," said Øystein Rekdal,
CEO of Lytix Biopharma. "We've seen continued strong clinical progress, notably
through our partnership with Verrica, where LTX-315 achieved a 97% calculated
objective response rate in a Phase II study for basal cell carcinoma. This
brings us closer to Phase III and, ultimately, commercialization. With an
expanded pipeline, robust scientific validation, and strengthened financial
position, Lytix is well positioned as we move into 2025, a year where we expect
to reach significant milestones that bring us closer to delivering our
immunotherapies to patients."

The Annual Report for 2024 is attached to this notice and is also available on
the company's website, www.lytixbiopharma.com, under Investors. 

For further information, please contact:

Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com
Phone: +47 952 60 512

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.